Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Cancer trials interruption in Latin America halts treatment for many
  • News

Cancer trials interruption in Latin America halts treatment for many

  • 21 June 2021
  • Myriam Vidal Valero
Cancer trials interruption in Latin America halts treatment for many
Total
17
Shares
17
0
0
0
0

The interruption of cancer clinical trials across Latin America due to the COVID-19 pandemic is threatening the treatment of thousands of patients in the public health system. A JCO Global Oncology study, conducted by the Latin American Cooperative Oncology Group (LACOG), showed temporary and complete interruptions of clinical cancer trials in 90 research sites across the region.

Although clinical trials have also been suspended in other parts of the world, including Europe, the Latin American medical community is becoming increasingly concerned. “The clinical trials represent sometimes the only opportunity that these patients have to access immunotherapy or targeted therapy,” said Aline Lara from Hospital Sírio-Libanês, São Paulo, the main author of the study.

Of the 90 participating centres, 45.6% reported COVID-related treatment delays that caused protocol deviations; 51.1% had cancellations and postponements of medical visits; 53.3% reported a decrease in patient attendance; and 36% experienced a loss of research staff during the pandemic.

Overall, 80% of the sites had temporary interruption to clinical trial accrual, usually because of a decision by a sponsor to only accept extremely good candidates for trials. According to the authors of the paper, such decisions were based on guidelines from the US Food and Drug Administration and European regulators that didn’t fit the reality of Latin American cancer treatment.

In light of this, 96.7% of the participating centres implemented other measures for trial participants and candidates during the COVID-19 pandemic, such as telemedicine, authorisation of special consent procedures, remote monitoring, remote site initiation visits and shipment of oral drugs directly to patients’ home. However, telemedicine practices are not well-suited to some patients who live in rural areas with no access to technology or internet. “The lesson for me is that it’s possible to maintain some important trials open if you think about strategy to minimise risk for those participants,” said Diogo Bastos from the Instituto do Câncer do Estado de São Paulo and one of the study authors.

Bastos thinks the responses to the survey demonstrate that experiences in Latin America are often different than reported in the USA and Europe. “I think we, as a region, should try to work together more often, try to conduct important studies, to assess our reality, which may be different, sometimes significantly different, than the one in Europe or North America,” he says.

“I think we should do it more often, and should do it together, because sometimes we only rely on data produced by other regions of the world that may not be applicable to our reality.”

The authors indicated that the consequences of clinical trial interruptions will continue to be seen in Latin America for a good while yet. There may also be opportunities for improvement in treatment access, policies, and enrolment protocols if research centres take this setback as an opening for change. “I think it’s not over yet,” Aline Lara said.

See also ‘A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?‘

Total
17
Shares
Share 17
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • covid-19
  • trials
Myriam Vidal Valero

Previous Article
  • Articles
  • Medicine

Innovations in supportive care: cancer treatment side effects

  • 18 June 2021
  • Rachel Brazil
View Post
Next Article
  • Obituaries

Bella Kaufman: a rare combination of humanity and morality

  • 24 June 2021
  • Anna Wagstaff
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.